Terms: = Breast cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
349 results:
1. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the treatment of TA-muc1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
Gellert J; Jäkel A; Danielczyk A; Goletz C; Lischke T; Flechner A; Dix L; Günzl A; Kehler P
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338686
[TBL] [Abstract] [Full Text] [Related]
2. Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology.
Li M; Zhao Y; Li H; Kang S; Deng X; Sheng M
Aging (Albany NY); 2024 Feb; 16(3):2848-2865. PubMed ID: 38329441
[TBL] [Abstract] [Full Text] [Related]
3. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
[TBL] [Abstract] [Full Text] [Related]
4. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer.
Cherifi F; Da Silva A; Martins-Branco D; Awada A; Nader-Marta G
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):45-59. PubMed ID: 38214896
[TBL] [Abstract] [Full Text] [Related]
6. CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects.
Wekking D; Leoni VP; Lambertini M; Dessì M; Pretta A; Cadoni A; Atzori L; Scartozzi M; Solinas C
Cytokine Growth Factor Rev; 2024 Feb; 75():57-64. PubMed ID: 37838584
[TBL] [Abstract] [Full Text] [Related]
7. The Therapeutic Effects of muc1-C shRNA@Fe
Li Z; Guo T; Zhao S; Lin M
Int J Nanomedicine; 2023; 18():5651-5670. PubMed ID: 37822991
[TBL] [Abstract] [Full Text] [Related]
8. Single Cell Phenotypic Analysis for cancer Stem Cell Identification by Dual-Isotope ICP-QMS.
Liu M; Wei X; Wu C; Liu J; Wei Y; Wang X; Chen ML; Yang T; Wang JH
Anal Chem; 2023 Sep; 95(38):14447-14454. PubMed ID: 37695163
[TBL] [Abstract] [Full Text] [Related]
9. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
10. Use of S2.2/DOX Magnetic Nanoliposomes in MR Molecule Imaging and Targeted Thermochemotherapy for breast cancer In Vitro.
Zhu Y; Yang D; Guo T; Lin M
Technol Cancer Res Treat; 2023; 22():15330338231194498. PubMed ID: 37563954
[TBL] [Abstract] [Full Text] [Related]
11. Surfaceome Profiling Suggests Potential of Anti-muc1×EGFR Bispecific Antibody for breast cancer Targeted Therapy.
Pourjafar M; Saidijam M; Miehe M; Najafi R; Soleimani M; Spillner E
J Immunother; 2023 Sep; 46(7):245-261. PubMed ID: 37493044
[TBL] [Abstract] [Full Text] [Related]
12. MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative breast cancer MDA-MB-231 Cells.
Pratelli G; Carlisi D; Di Liberto D; Notaro A; Giuliano M; D'Anneo A; Lauricella M; Emanuele S; Calvaruso G; De Blasio A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446326
[TBL] [Abstract] [Full Text] [Related]
13. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line treatment for Endocrine-Receptor-Positive Metastatic breast cancer.
Cejuela M; Gil-Torralvo A; Castilla MÁ; Domínguez-Cejudo MÁ; Falcón A; Benavent M; Molina-Pinelo S; Ruiz-Borrego M; Salvador Bofill J
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239834
[TBL] [Abstract] [Full Text] [Related]
14. A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.
Sur D; Lungulescu C; Dumitrescu EA; Afrăsânie V; Spînu Ș; Lungulescu CV; Schmoll HJ
Expert Rev Anticancer Ther; 2023 Jun; 23(6):633-641. PubMed ID: 37127555
[TBL] [Abstract] [Full Text] [Related]
15. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer.
Yin L; Chen GL; Xiang Z; Liu YL; Li XY; Bi JW; Wang Q
Biomed Pharmacother; 2023 Jun; 162():114648. PubMed ID: 37023621
[TBL] [Abstract] [Full Text] [Related]
16. Possible correlation of apical localization of muc1 glycoprotein with luminal A-like status of breast cancer.
Semba R; Horimoto Y; Sakata-Matsuzawa M; Ishizuka Y; Denda-Nagai K; Fujihira H; Noji M; Onagi H; Ichida M; Miura H; Watanabe J; Saito M; Saito T; Arakawa A; Irimura T
Sci Rep; 2023 Mar; 13(1):5281. PubMed ID: 37002293
[TBL] [Abstract] [Full Text] [Related]
17. treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.
Karanyotova S; Topova B; Petrova E; Doychev P; Kapitanska E; Petrova G; Mitkova Z; Dimitrova M
Front Public Health; 2023; 11():1073733. PubMed ID: 36935674
[TBL] [Abstract] [Full Text] [Related]
18. treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF; Möhn N; Witte T; Schefzyk M; Wiestler M; Lovric S; Hufendiek K; Schwenkenbecher P; Sühs KW; Friese MA; Klotz L; Pul R; Pawlitzki M; Hagin D; Kleinschnitz C; Meuth SG; Skripuletz T
Autoimmun Rev; 2023 May; 22(5):103312. PubMed ID: 36924922
[TBL] [Abstract] [Full Text] [Related]
19. Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer.
Zhu X; Bu J; Zhu T; Jiang Y
J Transl Med; 2023 Mar; 21(1):184. PubMed ID: 36895039
[TBL] [Abstract] [Full Text] [Related]
20. Integrated SERS-Vertical Flow Biosensor Enabling Multiplexed Quantitative Profiling of Serological Exosomal Proteins in Patients for Accurate breast cancer Subtyping.
Su X; Liu X; Xie Y; Chen M; Zheng C; Zhong H; Li M
ACS Nano; 2023 Feb; 17(4):4077-4088. PubMed ID: 36758150
[TBL] [Abstract] [Full Text] [Related]
[Next]
